GENE ONLINE|News &
Opinion
Blog

2022-10-06| Trials & Approvals

FDA Accepts and Boosts sBLA for Takeda’s HAE Treatment for Pediatric Patients

by Max Heirich
Share To

The United States Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for the potential expanded use of TAKHZYRO® (lanadelumab-flyo). Currently, TAKHZYRO has approval for hereditary angioedema (HAE) attack prevention in people 12 years of age and older.

The sBLA intends the expanded use of TAKHZYRO to pediatric patients 2 to <12 years of age. The basis for the expansion is the SPRING Study. If approved, TAKHZYRO would be the first prophylaxis treatment for HAE patients younger than six.

Related Article: Takeda Walks Away From Microbiome Deal With Finch

Preventing a Rare Disease’s Attacks

HAE is a rare inherited disorder wherein patients experience repeated instances of fluids accumulating outside of the blood vessels. This causes the blockage of normal blood flow, resulting in the swelling of the hands, feet, limbs, face, intestinal tract, or airway. Experts estimate that 50,000 – 150,000 people have this disease worldwide.

Treatments for the rare disease include BioCryst’s Orladeyo (berotralstat), an inhibitor of plasma kallikrein’s proteolytic activity. Plasma kallikrein plays a role in the body’s inflammatory response, specifically to do with the protein Factor XII.

TAKHZYRO is similarly a plasma kallikrein inhibitor. Initially gaining approval from the FDA in February of this year, Takeda’s inhibitor has since gained approvals in thirty other countries. However, Takeda returned to the FDA seeking extended approval for TAKHZYRO in October.

Expanding HAE Attack Prevention

Takeda submitted an sBLA to the FDA seeking the expansion of TAKHZYRO for the treatment of children younger than twelve. The basis of the sBLA was the SPRING Study, a Phase 3 clinical trial examining the effect of the inhibitor on HAE patients aged two to twelve.

The study demonstrated a 94.8% reduction in HAE attacks over a 52-week period of treatment. In addition, the efficacy and safety profile remained consistent with adult and adolescent groups in earlier studies. 

On the submission, Cheryl Schwartz, Senior Vice President, U.S. Rare Disease Business Unit at Takeda, said, “If TAKHZYRO is approved for this expanded use, children as young as two years old would have a treatment option which has shown proven effective prevention of HAE attacks in those over twelve years of age.”

The FDA accepted the sBLA, going so far as to grant it priority review. Takeda expects a decision within the first half of 2023. If approved, TAKHZYRO will be the first approved prophylaxis treatment for pediatric patients. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
R&D
Advancements in Alzheimer’s Disease Drug Innovation and Funding Programs in 2024
2024-07-04
FDA Greenlights Eli Lilly’s Groundbreaking Alzheimer’s Drug Kisunla for Early Symptomatic Treatment
2024-07-04
Tanvex BioPharma Secures Asia’s First FDA Approval for Filgrastim Biosimilar, Seizing a $403 Million Market
2024-07-03
LATEST
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
2024-07-18
EVENT
Scroll to Top